References
- National Cancer Institute. Cancer Trends Progress Report – 2011/2012 Update. National Cancer Institute; Bethesda, MD, USA. http://progressreport.cancer.gov/sites/default/files/archive/report2011.pdf. Accessed October 31, 2015
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2012. J Natl Cancer Inst 2011;103:117-28
- Klein IR, Boccia RV, Cannon E, et al. Evolving strategies for the management of multiple myeloma: a managed care perspective. Am J Manag Care 2014;20:S45-S60
- Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing. JAMA 2007;298:61-9
- Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Am J Manag Care 2011;17:SP38-SP44
- Ito K, Elkin E, Blinder V, et al. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer 2013;119:2494-502
- National Comprehensive Cancer Network. Multiple Myeloma. Version 2. 2015. National Comprehensive Cancer Network; Fort Washington, PA, USA. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed October 30, 2015
- National Cancer Institute 2015. SEER Stat Fact Sheets: Myeloma. National Cancer Institute; Bethesda, MD, USA. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed February 23, 2015
- Thalomid [package insert]. Summit, NJ: Celgene Corporation, 2015
- Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906-17
- Cook R. Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm 2008;14:S18-S11
- Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs 2013;36:301-8
- Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32:306-11
- Rajurkar SP, Presant CA, Bosserman LD, et al. A copay foundation assistance support program for patients receiving intravenous cancer therapy. J Oncol Pract 2011;7:100-2
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistency studies using retrospective databases. Value Health 2007;10:3-12
- Fairman K, Motherall B. Evaluating medication adherence: which measure is right for your program? J Manag Care Pharm 2000;6:499-506
- Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm 2009;15:648-58
- Happe LE, Clark D, Holliday E, et al. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Pharm 2014;20:677-84
- Silverman E 2013. Bye, bye co-pay cards? Why Express Scripts is excluding dozens of drugs. Forbes; Jersey City, NJ, USA. http://www.forbes.com/sites/edsilverman/2013/10/21/bye-bye-co-pay-cards-why-express-scripts-is-excluding-dozens-of-drugs/. Accessed October 30, 2015
- Franken A, Kirk M. Cancer Treatment Parity Act of 2013. United States Senators. Saint Paul, MN, USA; 2013. http://www.franken.senate.gov/files/documents/131220ChemoParity.pdf. Accessed October 31, 2015
- Mulcahy N 2015. ‘Parity’ laws for costly oral cancer drugs not a solution. Medscape Medical News; New York, NY, USA. http://www.medscape.com/viewarticle/832706. Accessed October 30, 2015